The psychedelic drugs market, valued at $4.08 billion in 2025, is experiencing significant growth and mainstream acceptance, driven by pharmaceutical industry interest and positive clinical trial results. Projections indicate the market will expand from $4.63 billion in 2026 to $8.75 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 13.55%. This shift is highlighted by the recent announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage psychedelic drug maker, for up to $3.8 billion, a move analysts are calling a major validation of the sector.
This embrace by Big Pharma signals a paradigm shift in psychiatry, with key opinion leaders anticipating these medications could represent the biggest change in the field. The FDA's Breakthrough Therapy Designation for BPL-003, currently in Phase 3 trials, further accelerates development and review, with Jefferies analysts projecting a potential $1-2 billion opportunity in treatment-resistant depression (TRD) if Phase 3 is successful by early 2029. Spravato, an FDA-approved ketamine-derived nasal spray from J&J, achieved $584 million in sales, up 40% year-over-year, and is expected to exceed $2 billion in sales for the current year.
Psychedelic substances like psilocybin, MDMA, ayahuasca, and ibogaine are under investigation for a range of mental health issues including depression, post-traumatic stress disorder, eating disorders, and addiction. While Eli Lilly's acquisition of AtaiBeckley is seen as a strong endorsement, analysts caution that not all psychedelic biotechs will benefit equally. However, this move by a major pharmaceutical company significantly raises the bar for clinical maturity, indication selection, and overall scalability within the psychedelics space.
